Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.

References

• Tatman P, Fringuello A, Graner M, et al. Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity. J Clin Oncol. 2020;38:15_suppl, e15663-e15663.
   Web of Science ®Google Scholar
• Peeters BW, Tonnaer JA, Groen MB, et al. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress. 2004;7:233–241.
   PubMed Web of Science ®Google Scholar
• Joshi T, Johnson M, Newton R, et al. The long-acting β2 - adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner. Br J Pharmacol. 2015;172:2634–2653.
   PubMed Web of Science ®Google Scholar
• Kesel AJ, Huang Z, Murray MG, et al. Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire. Antivir Chem Chemother. 2014;23:197–215.
   PubMedGoogle Scholar
• Christopher DV, Patel MM, Xu A, et al. A phase 1 clinical trial to evaluate pharmacodynamic interactions after oral coadministration of alcohol and the highly selective glucocorticoid receptor antagonist, PT150. Neuropsychopharmacology. 2019;44:189–190.
   Web of Science ®Google Scholar
• Investigator’s Brochure on ORG 34517, Edition No. 12. 2009, unpublished (available under confidential disclosure agreement).
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.
   PubMed Web of Science ®Google Scholar
• Ghazizadeh Z, Majd H, Richter M, et al. Androgen regulates SARS-COV-2 receptor levels and is associated with severe COVID-19 symptoms in men. Version 2. bioRxiv. 2020 May 15;2020.05.12.091082. DOI:10.1101/2020.05.12.091082.
   PubMedGoogle Scholar
• Bhowmick NA, Oft J, Dorff T, et al. COVID-19 and androgen targeted therapy for prostate cancer patients. Endocr Relat Cancer. 2020 Jun 1;ERC-20-0165.R1. DOI:10.1530/ERC-20-0165.
   Web of Science ®Google Scholar
• Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen meiated. J Am Acad Dermatol. 2020;83:308–309.
   PubMed Web of Science ®Google Scholar
• Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020;8:659-660.
   Web of Science ®Google Scholar
• Heneka MT, Golenbock D, Latz E, et al. Immediate and longterm consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12:69.
   PubMed Web of Science ®Google Scholar
• Reynolds AR, Saunders MA, Brewton HW, et al. Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation. Drug Alcohol Depend. 2015;154:100–104.
   PubMed Web of Science ®Google Scholar
• Bachmann CG, Linthorst ACE, Holsboer F, et al. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology. 2003;28:1056–1067.
   PubMed Web of Science ®Google Scholar
• Ang-Bleuel A, Ulbricht S, Chandramohan Y, et al. Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response. Eur J Neurosci. 2005;22:1691–1700.
   PubMed Web of Science ®Google Scholar
• Johnson DA, Grant EJ, Ingram CD, et al. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol Psychiatry. 2007;62:1228–1235.
   PubMed Web of Science ®Google Scholar
• Groenink L, Dirks A, Verdouw PM, et al. CRF1 not glucocorticoid receptors mediate prepulse inhibition deficits in mice overexpressing CRF. Biol Psychiatry. 2008;63:360–368.
   PubMed Web of Science ®Google Scholar
• Rice BA, Saunders MA, Jagielo-Miller JE, et al. Repeated subcutaneous administration of PT150 has dose-dependent effects on sign tracking in male Japanese quail. Exp Clin Psychopharmacol. 2019;27:515–521.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12:eabb5883. .
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. TMPRSS2 transmembrane serine protease 2 [Homo sapiens (human)] Gene ID: 7113; 2020 March 13 [cited 2020 Apr 2]. Available from: https://www.ncbi.nlm.nih.gov/gene/7113.
   Google Scholar
• Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4:1310–1325.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang Q, Xia X, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020 Jun 19. DOI:10.1111/acel.13168.
   Web of Science ®Google Scholar
• Heurich A, Hofmann-Winkler H, Gierer S, et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88:1293–1307.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Zheng KI, Gao F, Wang XB, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020Apr;19:154244.
   Google Scholar
• Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020 May 1;382:2582.
   Web of Science ®Google Scholar
• Russell G, Lightman S. The human stress response. Nat Rev Endocrinol. 2019;15:525–534.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20:1849–1858. .
   Google Scholar
• Panesar NS, Lam CW, Chan MH, et al. Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol. Eur J Clin Invest. 2004;34:382–384.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475.
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Tyler KLCOVID-19. COVID −19: a global threat to the nervous system. Ann Neurol. 2020 Jun 7;88:1–11.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson J, et al. Effet of dexamethasone in hospitalied patients with COVID-19: preliminary report. Preprint at. medRxiv. 2020. DOI:10.1101/2020.06.22.20137273.
   Google Scholar
• Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582:469.
   PubMed Web of Science ®Google Scholar
• Liu T, Luo S, Libby P, et al. Cathepsin L-selective inhibitors: a potentially promisng treament for COVID-19 patients.
   Google Scholar
• Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. virology. 2009;395:210–222.
   Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–497.
   Google Scholar